Biomarin Pharmaceutical Valuation
| BMRN Stock | USD 71.24 0.36 0.50% |
At this time, the firm appears to be overvalued. Biomarin Pharmaceutical shows a prevailing Real Value of $50.58 per share. The current price of the firm is $71.24. Our model approximates the value of Biomarin Pharmaceutical from analyzing the firm fundamentals such as Return On Equity of 0.0805, current valuation of 13.06 B, and Profit Margin of 0.15 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Biomarin Pharmaceutical's valuation include:
Price Book 2.4021 | Enterprise Value | Enterprise Value Ebitda 20.0698 | Price Sales 4.7622 | Forward PE 17.8253 |
Overvalued
Today
Please note that Biomarin Pharmaceutical's price fluctuation is very steady at this time. Calculation of the real value of Biomarin Pharmaceutical is based on 3 months time horizon. Increasing Biomarin Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biomarin Pharmaceutical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biomarin Stock. However, Biomarin Pharmaceutical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 71.24 | Real 50.58 | Target 97.66 | Hype 71.24 | Naive 71.38 |
The intrinsic value of Biomarin Pharmaceutical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biomarin Pharmaceutical's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Biomarin Pharmaceutical helps investors to forecast how Biomarin stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biomarin Pharmaceutical more accurately as focusing exclusively on Biomarin Pharmaceutical's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Biomarin Pharmaceutical's intrinsic value based on its ongoing forecasts of Biomarin Pharmaceutical's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Biomarin Pharmaceutical's closest peers.
Biomarin Pharmaceutical Cash |
|
Biomarin Valuation Trend
Knowing Biomarin Pharmaceutical's actual value is paramount for traders when making sound investment determinations. Using both Biomarin Pharmaceutical's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Biomarin Revenue by Product
Biomarin Pharmaceutical Total Value Analysis
Biomarin Pharmaceutical is currently projected to have valuation of 13.06 B with market capitalization of 13.59 B, debt of 602.71 M, and cash on hands of 1.27 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biomarin Pharmaceutical fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
13.06 B | 13.59 B | 602.71 M | 1.27 B |
Biomarin Pharmaceutical Investor Information
About 99.0% of the company shares are held by institutions such as insurance companies. The book value of Biomarin Pharmaceutical was currently reported as 29.66. The company has Price/Earnings To Growth (PEG) ratio of 0.49. Biomarin Pharmaceutical had not issued any dividends in recent years. Biomarin Pharmaceutical is performing exceptionally good at this time. It has a great odds to report excellent financial results in April.Biomarin Pharmaceutical Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biomarin Pharmaceutical has an asset utilization ratio of 40.83 percent. This suggests that the Company is making $0.41 for each dollar of assets. An increasing asset utilization means that Biomarin Pharmaceutical is more efficient with each dollar of assets it utilizes for everyday operations.Biomarin Pharmaceutical Ownership Allocation
Biomarin Pharmaceutical holds a total of 190.78 Million outstanding shares. The majority of Biomarin Pharmaceutical outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Biomarin Pharmaceutical to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Biomarin Pharmaceutical. Please pay attention to any change in the institutional holdings of Biomarin Pharmaceutical as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Biomarin Pharmaceutical Profitability Analysis
The company reported the previous year's revenue of 2.85 B. Net Income was 426.86 M with profit before overhead, payroll, taxes, and interest of 2.27 B.About Biomarin Pharmaceutical Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Biomarin Pharmaceutical. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Biomarin Pharmaceutical based exclusively on its fundamental and basic technical indicators. By analyzing Biomarin Pharmaceutical's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Biomarin Pharmaceutical's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Biomarin Pharmaceutical. We calculate exposure to Biomarin Pharmaceutical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biomarin Pharmaceutical's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2.3 B | 2.4 B | |
| Pretax Profit Margin | 0.19 | 0.20 | |
| Operating Profit Margin | 0.17 | 0.18 | |
| Net Profit Margin | 0.15 | 0.16 | |
| Gross Profit Margin | 0.80 | 1.01 |
Biomarin Pharmaceutical Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 196.7 M | |
| Quarterly Earnings Growth Y O Y | 6.449 | |
| Forward Price Earnings | 17.8253 |
Biomarin Pharmaceutical Current Valuation Indicators
Biomarin Pharmaceutical's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Biomarin Pharmaceutical's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Biomarin Pharmaceutical, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Biomarin Pharmaceutical's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Biomarin Pharmaceutical's worth.When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.449 | Earnings Share 2.21 | Revenue Per Share | Quarterly Revenue Growth 0.156 | Return On Assets |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.